Sign In
Buy CAR
$173.86
+1.48 (+0.86%)
At Close: Jun 03, 2026
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
01:09pm, Wednesday, 12'th Jun 2024
Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. R
Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to an acceptable safety profile, and potentia
New Strong Sell Stocks for June 7th
07:26am, Friday, 07'th Jun 2024
A, CAR and BGS have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2024.
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKV
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymph
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
05:00pm, Thursday, 23'rd May 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical deve
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
07:30am, Tuesday, 21'st May 2024
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif. , May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "C
Higher inflation in 2024 likely: NABE
09:26am, Monday, 20'th May 2024
Inflation is likely to stick around at higher-than-desired levels for the rest of the year, according to a new survey by America’s top economists. "With the higher inflation expectations, panelists
Meridian Wealth Management LLC Sells 3,300 Shares of PACCAR Inc (NASDAQ:PCAR)
07:26am, Monday, 20'th May 2024
Meridian Wealth Management LLC trimmed its holdings in shares of PACCAR Inc (NASDAQ:PCAR – Free Report) by 49.5% in the 4th quarter, according to its most recent Form 13F filing with the Securit
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointme
National Bank of Canada FI Grows Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
05:06am, Monday, 20'th May 2024
National Bank of Canada FI boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 200.0% during the 4th quarter, according to the company in its most recent disc
HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)
01:38am, Monday, 20'th May 2024
Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 earnings estimates for Mustang Bio in a research note issued to investors on Thursday, May 1
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
01:18am, Monday, 20'th May 2024
Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar
